Vasoactive Intestinal Peptide
Also known as VIP · vasoactive intestinal polypeptide
Rapid-acting vasoactive neuropeptide with experimental use in pulmonary and immune settings.
Clinical Stage
This is a clinical-stage therapeutic, not a typical consumer RUO product. Information is provided for educational context about ongoing clinical research.
Evidence visual
Vasoactive Intestinal Peptide evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
medium
Regulatory
not approved
WADA
none
FDA
unknown
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
VIP is a 28-amino-acid neuropeptide with strong vasodilatory and immunomodulatory effects. Human use is limited to small studies and specialist contexts, with practical barriers including very short half-life and hypotension risk. It is not a typical consumer peptide and should be treated as an advanced experimental tool.
Decision path
Where Vasoactive Intestinal Peptide fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Vasoactive Intestinal Peptide belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
VPAC receptor agonism increases cAMP, relaxes vascular smooth muscle, and modulates inflammatory signaling.
subcutaneous, intravenous
Human research typically uses infusion or microgram-range parenteral dosing rather than consumer-style cycles.
Vasodilation, pulmonary vascular effects, and anti-inflammatory signaling in narrow research contexts.
Hemodynamic effects occur within minutes; sustained protocols are needed for longer exposure.
Avoid in hypotension, hypovolemia, or settings where strong vasodilation is unsafe.
Hypotension, flushing, tachycardia, headache, diarrhea, and infusion intolerance.
Likely additive with other blood-pressure-lowering or vasodilating agents.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Known Interactions
Both can shift vascular tone; combined use raises hypotension and perfusion-management uncertainty.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Vasoactive Intestinal Peptide.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.